Abstracts tagged "neutropenia"

Abstract Number: 1940 • 2018 ACR/ARHP Annual Meeting
Reductions in Absolute Neutrophil Count (ANC) with Sarilumab Resulting in Dose Delays or Dose Decreases: Effects on Efficacy and Safety
Jeffrey R. Curtis¹, Gregory St. John², Michael Pannucci², Yong Lin³, José A. Maldonado-Cocco⁴, Tom W.J. Huizinga⁵, Marina Stanislav⁶ and Paul Emery⁷, ¹University of Alabama, Birmingham, AL, ²Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ³Sanofi Genzyme, Bridgewater, NJ, ⁴Universidad de Buenos Aires, Buenos Aires, Argentina, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russian Federation, ⁷University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom
Background/Purpose: In sarilumab randomized controlled trials (RCTs), dose delay and/or reduction was recommended for management of patients who developed neutropenia Grade (G) 3 (ANC ≥500…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 1530 • 2015 ACR/ARHP Annual Meeting
Neutrophil Function and Survival Unaffected in Healthy Subjects Following Single Administration of Tocilizumab
Laurence Lok¹, Jatinder Juss¹, Neda Farahi¹, Chrystalla Loutsios¹, Chandra Solanki², Adrien Michael Peters³, Sophie Dimonaco⁴, Francis Donaldson⁴, Benjamin Porter-Brown⁴ and Edwin Chilvers¹, ¹Department of Medicine, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, ²Department of Nuclear Medicine, Cambridge University Hospitals, Cambridge, United Kingdom, ³Division of Clinical and Laboratory Investigation, Brighton and Sussex Medical School, Brighton, United Kingdom, ⁴Roche Products Ltd., Welwyn Garden City, United Kingdom
Background/Purpose: Decreases in circulating neutrophil counts have been observed in adults with rheumatoid arthritis (RA) and children with systemic or polyarticular juvenile idiopathic arthritis treated…
Abstract Number: 2903 • 2015 ACR/ARHP Annual Meeting
Late-Onset Neutropenia Following Rituximab Treatment in Patients with Systemic Lupus Erythematosus
Ioannis Parodis, Frida Söder, Ronald F. van Vollenhoven, Elisabet Svenungsson and Iva Gunnarsson, Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: The incidence and clinical consequences of rituximab-mediated late-onset neutropenia (LON) have been studied in various diseases, but data from Systemic Lupus Erythematosus (SLE) are…
Abstract Number: 680 • 2014 ACR/ARHP Annual Meeting
Influence of Antimalarial doesn´t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus
Eugenia Enriquez Merayo¹, Maria Galindo Izquierdo², Esther Rodriguez-Almaraz³, Maria Martin Lopez², Otto Martin Olivas Vergara⁴, Patricia E. Carreira⁵ and Isabel Mateo⁶, ¹RHEUMATOLOGY, 12 DE OCTUBRE, MADRID, Spain, ²RHEUMATOLOGY, HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ³Department of Rheumatology. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁴HOSPITAL 12 DE OCTUBRE, MADRID, Spain, ⁵Rheumatology Department. Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Servicio De Reumatología, Hospital 12 De Octubre,, Madrid, Spain
Background/Purpose: To analyze the effect of antimalarials (AM) as preventive factor for the development of severe cytopenias and in their outcome after treatment in a…
Abstract Number: 2489 • 2014 ACR/ARHP Annual Meeting
Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis
V. Strand¹, A. Dikranian², J. Beal³, K. Kwok³, S. Krishnaswami⁴, S. Wood⁴ and C. Nduaka⁴, ¹Biopharmaceutical Consultant, Portola Valley, CA, ²San Diego Arthritis Medical Clinic, San Diego, CA, ³Pfizer Inc, New York, NY, ⁴Pfizer Inc, Groton, CT
Background/Purpose: Tofacitinib is an oral Janus kinase (JAK) inhibitor for the treatment of rheumatoid arthritis (RA). Post-baseline (BL) decreases in mean peripheral neutrophil count were…
Abstract Number: 273 • 2013 ACR/ARHP Annual Meeting
Neutropenia With Tocilizumab Treatment Is Not Associated With Increased Infection Risk In Patients With Systemic Juvenile Idiopathic Arthritis
Fabrizio De Benedetti¹, Hermine Brunner², Eileen M. Baildam³, Ruben Burgos-Vargas³, Gerd Horneff³, Hans-Iko Huppertz³, Kirsten Minden⁴, Barry L. Myones², Karen Onel⁵, Jianmei Wang⁶, Kamal N. Bharucha⁷, Daniel J. Lovell², Alberto Martini⁸ and Nicolino Ruperto³, ¹IRCCS Ospedale Pediatrico Bambino Gesú, Rome, Italy, ²PRCSG, Cincinnati, OH, ³PRINTO, Genoa, Italy, ⁴Children’s University Hospital Charite/German Rheumatism Research Centre Berlin, Berlin, Germany, ⁵Pediatric Rheumatology, University of Chicago Hospitals, Chicago, IL, ⁶Roche Products Ltd., Welwyn Garden City, United Kingdom, ⁷Genentech, South San Francisco, CA, ⁸Pediatria II, Istituto Giannina Gaslini, Genova, Italy
Background/Purpose: In the phase 3 TENDER trial of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA), decreases in neutrophil count were commonly observed.…
Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting
Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Jean Hugues Salmon¹, Patrice Cacoub², Bernard G. Combe³, Jean Sibilia⁴, Beatrice Pallot Prades⁵, Olivier Fain⁶, Alain G. Cantagrel⁷, Maxime Dougados⁸, Olivier Meyer⁹, Philippe Carli¹⁰, Edouard Pertuiset¹¹, Isabelle Pane¹², Philippe Ravaud¹³, Xavier Mariette¹⁴ and Jacques-Eric Gottenberg¹⁵, ¹Rheumatology, Reims, France, ²Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ³Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ⁵Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁶Internal Medicine, Jean Verdier Hospital, Bondy, France, ⁷Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁸Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰HIA sainte Anne, Toulon, France, ¹¹Rheumatology, Ch Rene Dubos, Pontoise, France, ¹²Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁵Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
Abstract Number: 1302 • 2012 ACR/ARHP Annual Meeting
Early Neutropenia Is Associated with Clinical Response in Patients Receiving Tocilizumab in Rheumatoid Arthritis
Marie Kostine¹, Thomas Barnetche², Elodie Ardouin³, Marlene Joly⁴, Emilie Rabois⁵, Baptiste Glace Sr.⁶, Delphine Nigon⁷, Thierry Schaeverbeke⁸ and Christophe Richez⁹, ¹Rheumatology, CHU Pellegrin, Bordeaux, France, ²Rheumatology, CHU Bordeaux Pellegrin, Bordeaux, France, ³Rheumatology, Limoges University Hospital, Limoges, France, ⁴Rheumatology, Montpellier University Hospital, Montpellier, France, ⁵Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ⁶Rheumatology, Rheumatology CHU Gabriel Montpied, Clermont-Ferrand, France, ⁷CHU Purpan, Toulouse, France, ⁸Service de Rhumatologie, Groupe Hospitalier Pellegrin, Bordeaux, France, ⁹Hôpital Pellegrin and Université Victor Segalen Bordeaux, France
Background/Purpose: A reduction in peripheral blood neutrophils count is usually observed with the anti-interleukin (IL) 6 receptor antibody tocilizumab. This often appears few days after…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].